Bioniche Terminates Trophogen License Agreement

Bioniche Life Sciences Inc. (TSX:BNC, ASX:BNC), a Canadian biopharmaceutical company, announced that its exclusive global veterinary license agreement with Trophogen Inc. has been terminated.

As quoted in the press release:

The agreement was originally entered into in June, 2010 to provide commercial access for Bioniche to a patented, proprietary superagonist hormone technology platform developed by Trophogen (originally licensed from the National Institutes of Health) in the veterinary field.

Click here to read the full Bioniche Life Sciences Inc. (TSX:BNC, ASX:BNC) press release.